TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07704099: A Multicenter, Phase 2, Open-Label Study Evaluating the Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

Sponsor: Keros Therapeutics, Inc. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,162,500

Rescue Site Savings

+$9,373,000

Unlock Full NCT07704099 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07704099 Rescue Dossier →